The effect of testosterone replacement theraphy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes

European Journal of Endocrinology

Volumn 156, Issue 5, 2007, Pages 595-602

  Kapoor, D ^a,c   Clarke, S ^c   Stanworth, R ^a,c   Channer, K S ^b   Jones, T Hugh ^a,c  

^a BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; GLICLAZIDE; INSULIN; INTERLEUKIN 6; LEPTIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ORAL ANTIDIABETIC AGENT; PLACEBO; RESISTIN; TESTOSTERONE; TESTOSTERONE DECANOATE; TESTOSTERONE DERIVATIVE; TESTOSTERONE ISOCAPROATE; TESTOSTERONE PHENYLPROPIONATE; TESTOSTERONE PROPIONATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIABETIC DIET; DIABETIC PATIENT; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

ADIPONECTIN; AGED; BODY COMPOSITION; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; PEPTIDE HORMONES; RESISTIN; STATISTICS, NONPARAMETRIC; TESTOSTERONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249103249     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0737     Document Type: Article

References (51)

1. Pittas AG, Joseph NA & Greenberg A. Adipocytokines and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2004 89 447-452.
2. Kershaw EE & Flier JS. Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism 2004 89 2548-2556.
3. Valsamakis G, McTernan PP, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AA & Kumar S. Modest weight loss and reduction in waist circumference after medical treatment are associated with favourable changes in serum adipocytokines. Metabolism 2004 53 430-434.
4. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Annals of Internal Medicine 1999 130 671-680.
5. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo, K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T & Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 1999 257 79-83.
6. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE & Goldstein BJ. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosightazone. Journal of Clinical Endocrinology and Metabolism 2002 87 5662-5667.
7. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE & Tataranni PA. Hypoadiponectinemia in obesity and Type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 2001 86 1930-1935.
8. Hasegawa G, Ohta M, Ichida Y, Obayashi H, Shigeta M, Yamasaki M, Fukui M, Yoshikawa T & Nakkamura N. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetologica 2005 42 104-109.
9. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S & Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor alpha, in vivo. Journal of Clinical Endocrinology and Metabolism 1997 82 4196-4200.
10. Kapoor D, Malkin CJ, Channer KS & Jones TH. Androgens, insulin resistance and vascular disease in men. Clinical Endocrinology 2005 63 239-250.
11. Barrett-Connor E, Khaw KT & Yen SS. Endogenous sex hormone levels in older men with diabetes mellitus. American Journal of Epidemiology 1990 132 895-901.
12. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non insulin-dependent diabetes mellitus. Annals of Internal Medicine 1992 117 807-811.
13. Andersson B, Marin P, Lissner L, Vermeulen A & Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994 17 405-411.
14. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A & Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in Type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2004 89 5462-5468.
15. Kapoor D, Goodwin E, Charmer KS & Jones TH. Testosterone reduces insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with Type 2 diabetes. European Journal of Endocrinology 2006 154 899-906.
16. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS & Rosenfeld RS. Plasma free and non sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. Journal of Clinical Endocrinology and Metabolism 1990 71 929-931.
17. Haffner SM, Valdez RA, Stern MP & Katz MS. Obesity, body fat distribution and sex hormones in men. International Journal of Obesity 1993 17 643-649.
18. Cohen PG. The hypogonadal-obesity cycle. Medical Hypotheses 1999 52 49-51.
19. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G & Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity and Related Metabolic Disorders 1992 16 991-997.
20. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ & Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. Journal of Clinical Endocrinology and Metabolism 1999 89 2647-2653.
21. Luukkaa V. Pesonen U, Huhtaniemi I, Lehtonen A, Tilvis R, Tuomilehto J, Koulu M & Huupponen R. Inverse correlation between serum testosterone and leptin in men. Journal of Clinical Endocrinology and Metabolism 1998 83 3243-3246.
22. Behre HM, Simoni M & Nieschlag E. Strong association between serum levels of leptin and testosterone in men. Clinical Endocrinology 1997 47 237-240,
23. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A & Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. Journal of Clinical Endocrinology and Metabolism 1999 84 3673-3680.
24. Jockenhovel F, Blum WF, Vogel E, Englaro P, Muller-Wieland D, Reinwein D, Rascher W & Krone W. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 1997 82 2510-2513.
25. Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P & Ross C. Testosterone replacement in older hypogonadai men: a 12-month randomised controlled trial. Journal of Clinical Endocrinology and Metabolism 1997 82 1659-1660.
26. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino, Y, Funahashi T & Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin sensitising adipocyte-derived protein. Diabetes 2002 51 2734-2741.
27. Lanfranco F, Zitzmann M, Simoni M & Nieschlag E. Serum adiponectin levels in hypogonadal men: influence of testosterone replacement therapy. Clinical Endocrinology 2004 60 500-507.
28. Page ST, Herbst KL, Amory JK, Coviello AD, Anawalt BD, Matsumoto AM & Bremner WJ. Testosterone administration suppresses adiponectin levels in men. Journal of Andrology 2005 26 1-13.
29. Malkin CJ, Pugh PJ, Kapoor D, Jones RD, Charmer KS & Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2004 89 3313-3318.
30. Lambert CP, Sullivan DH & Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha and leptin in elderly men ingesting megestrol acetate: a randomised controlled trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2003 58 165-170.
31. Khosla S, Atkinson EJ, Dunstan CR & O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism 2002 87 1550-1554.
32. Corrales JJ, Almeida M, Burgo R, Mories MT, Miralles JM & Orfao A. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. Journal of Endocrinology 2006 189 595-604.
33. Rifai N & Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary disease. Clinical Chemistry 2001 47 403-411.
34. Pradhan AD, Manson JE, Rifai N, Buring JE & Ridker PM. C-reactive protein, interleukin-6 and risk of developing type 2 diabetes. JAMA 2001 286 327-334.
35. Nieschtag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W & Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. International Journal of Andrology 2005 28 125-127.
36. Kapoor D, Aldred H, Clarke S, Charmer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with Type 2 diabetes mellitus - correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007 (in press).
37. Morley JE, Chariton E, Patrick P, Kaiser FE, Cadeau P, McCready D & Perry HM 111. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000 49 1239-1242.
38. Tremblay RR & Dube JY. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 1974 10 599-605.
39. Gomez JM, Maravall FJ, Gomez N, Navarro MA, Casamitjana R & Soler J. Interactions between serum leptin, the insulin-like growth factor-1 system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected. Clinical Endocrinology 2003 58 213-219.
40. Abdella NA, Mojiminiyi OA, Moussa MA, Zaki M, Al Mohammedi H, Al Ozairi ES & Al Jebely S. Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. Diabetic Medicine 2005 22 278-285.
41. Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M, Lemort N, Thibult N, Joubert E, Balkan B & Eschwege E. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone. Diabetes Care 2001 24 2149-2151.
42. Rolf C, Eckardstein SV, Koken U & Nieschlag E. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study. European Journal of Endocrinology 2002 146 505-511.
43. Haffner SM, Miettinen H, Karhapaa P, Mykkanen L & Laakso M. Leptin concentrations, sex hormones and cortisol in nondiabetic men. Journal of Clinical Endocrinology and Metabolism 1997 82 1807-1809.
44. Bjorntorp P. The regulation of adipose tissue distribution in humans. International Journal of Obesity and Related Metabolic Disorders 1996 20 291-302.
45. Wabitsch M, Blum WF, Muche R, Braun M, Hube F, Rascher W, Heinze E, Teller W & Hauner H. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. Journal of Clinical Investigation 1997 15 808-813.
46. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ & Tenover JL. Exogenous testosterone alone or with Finasteride increases physical performance, grip strength and lean body mass in older men with low serum testosterone. Journal of Clinical Endocrinology and Metabolism 2005 90 1502-1510.
47. Ling C, Kindblom J, Wennbo H & Billig H. Increased resistin expression in the adipose tissue of male prolactin transgenic mice and in male mice with elevated androgen levels. FEBS Letters 2001 507 147-150.
48. Maggio M, Basaria S, Ble A, Lauretani F, Bandinelli S, Ceda GP, Valenti G, Ling SM & Ferrucci L. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. Journal of Clinical Endocrinology and Metabolism 2006 91 345-347.
49. Yang YM, Lv XY, Huang WD, Xu ZR & Wu LJ. Study of androgen and atherosclerosis in old age male. Journal of Zhejiang University Science B 2005 6 931-935.
50. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N & Bhasin S. The effects of varying doses of testosterone on insulin sensitivity, plasma lipids, apolipoproteins and C-reactive protein in healthy young men. Journal of Clinical Endocrinology and Metabolism 2002 87 136-143.
51. Ng MK, Liu PY, Williams AJ, Nakhla S, Ly LP, Handelsman DJ & Celermajer DS. Prospective study of effect of androgens on serum inflammatory markers in men. Arteriosclerosis, Thrombosis and Vascular Biology 2002 22 1136-1141.